Skip Navigation



NDT Advance Access published online on June 9, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl293
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/9/2507    most recent
gfl293v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Takahashi, A.
Right arrow Articles by Dohi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, A.
Right arrow Articles by Dohi, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received November 9, 2005
Accepted April 28, 2006

Original Article

Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study

Akihiko Takahashi 1, Hiroyuki Takase 1, Takayuki Toriyama 1, Tomonori Sugiura 1, Yutaka Kurita 2, Ryuzo Ueda 3, and Yasuaki Dohi 3 *

1 Department of Internal Medicine, Enshu General Hospital, Hamamatsu, Japan
2 Department of Urology, Enshu General Hospital, Hamamatsu, Japan
3 Internal Medicine and Molecular Science, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan

* To whom correspondence should be addressed.
Yasuaki Dohi, E-mail: ydohi{at}med.nagoya-cu.ac.jp



  Abstract

Background. Cardiovascular events are the major determinants of the prognosis of patients on chronic haemodialysis. The present study was designed to investigate whether candesartan, an angiotensin II type-1 receptor blocker, reduces the incidence of cardiovascular events in these patients.

Methods. A total of 80 chronic haemodialysis patients (male/female, 47/33; mean age ± SEM, 61 ± 1 years) in stable condition and with no clinical evidence of cardiac disorders were enrolled. Patients were randomly assigned candesartan 4-8 mg/day (candesartan group; n = 43) or nothing (control group; n = 37), and followed for 19.4 ± 1.2 months with as endpoint cardiovascular events such as fatal/nonfatal myocardial infarction, unstable angina pectoris, congestive heart failure, severe arrhythmia and sudden death.

Results. Both groups exhibited similar clinical characteristics at baseline. During follow-up, cardiovascular events occurred in seven patients in the candesartan group and 17 in the control group. Kaplan-Meier analysis revealed that cardiovascular events and mortality rates were significantly (P < 0.01) higher in the control group than in the candesartan group (45.9 vs 16.3% and 18.9 vs 0.0%, respectively).

Conclusions. Candesartan therapy significantly reduces cardiovascular events and mortality in patients on chronic maintenance haemodialysis and therefore improves the prognosis of these patients.

Keywords: angiotensin receptor antagonists; brain natriuretic peptide; cardiovascular disease; cardiovascular mortality; congestive heart failure; randomized trail.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
W. L. Baker, C. I. Coleman, J. Kluger, K. M. Reinhart, R. Talati, R. Quercia, O. J. Phung, and C. M. White
Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease
Ann Intern Med, October 19, 2009; (2009) 0000605-200912150-00162v1.
[Abstract] [Full Text]

Home page
 Ther Adv Cardiovasc DisHome page
H. Suzuki
Therapeutic efficacy of renin--angiotensin blockade in patients receiving dialysis
Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 397 - 405.
[Abstract] [PDF]

Home page
 QJMHome page
S. Hirsch
The internist's role in treating hypertension in hemodialysis patients
QJM, July 1, 2009; 102(7): 501 - 507.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. Agarwal and A. D. Sinha
Cardiovascular Protection With Antihypertensive Drugs in Dialysis Patients: Systematic Review and Meta-Analysis
Hypertension, May 1, 2009; 53(5): 860 - 866.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
M. M. Sood, R. P. Pauly, C. Rigatto, and P. Komenda
Left ventricular dysfunction in the haemodialysis population
NDT Plus, August 1, 2008; 1(4): 199 - 205.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
E. Ritz and C. Wanner
The Challenge of Sudden Death in Dialysis Patients
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 920 - 929.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Covic, P. Gusbeth-Tatomir, and D. Goldsmith
Negative outcome studies in end-stage renal disease: how dark are the storm clouds?
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 56 - 61.
[Full Text] [PDF]

Home page
 CJASNHome page
C. A. Herzog
Can We Prevent Sudden Cardiac Death in Dialysis Patients?
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 410 - 412.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Almirall, M. P. Valenzuela, and T. Lopez
Candesartan reduces cardiovascular events in patients on chronic haemodialysis
Nephrol. Dial. Transplant., January 1, 2007; 22(1): 281 - 281.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.